ARUP's Laboratory Test Directory
| 0098581: Prostate Specific Antigen, Ultrasensitive |
| Test Mnemonic: PSA ULTRA | |
|
Methodology: Electrochemiluminescent Immunoassay
Performed: Sun-Sat Reported: Within 24 hours |
| Specimen Required: | |
|
Collect: One 4 mL plain red or PST. Also acceptable: green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Transport: 1 mL serum or plasma, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Remarks: Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP. Unacceptable Conditions: Grossly hemolyzed specimens. Stability: After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 6 months |
|
| Reference Interval: |
| 0.00-4.00 ng/mL |
| Interpretive Data: | |
|
After radical prostatectomy, the reference interval is less than 0.05 ng/mL if there is no residual disease. In healthy males without prostatectomy, the reference interval is 4.00 ng/mL or less. Lower limit of detection is 0.01 ng/mL. The Roche Modular E170 PSA electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche Modular E170 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche Modular E170 PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with nonprostatic carcinoma. |
| CPT Code(s): | |
| 84153 |